Patents by Inventor Robert Jason Herr

Robert Jason Herr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11117884
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 14, 2021
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Publication number: 20210061848
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: April 8, 2020
    Publication date: March 4, 2021
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Robert Jason Herr, Robert Borbo Kargbo
  • Publication number: 20210061790
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 15, 2018
    Publication date: March 4, 2021
    Inventors: Aimee CROMBIE SPEERSCHNEIDER, Dennis SHINJI YAMASHITA, Philip Michael PITIS, Michael John HAWKINS, Guodong Liu, Tamara Ann MISKOWSKI DAUBERT, Catherine C.K. YUAN, Robert BORBO KARGBO, Robert Jason HERR, Donna ROMERO
  • Publication number: 20210061812
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 15, 2018
    Publication date: March 4, 2021
    Inventors: Aimee CROMBIE SPEERSCHNEIDER, Dennis SHINJI YAMASHITA, Philip Michael PITIS, Michael John HAWKINS, Guodong Liu, Tamara Ann MISKOWSKI DAUBERT, Catherine C.K. YUAN, Robert BORBO KARGBO, Robert Jason HERR, Donna ROMERO
  • Publication number: 20200231564
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 27, 2019
    Publication date: July 23, 2020
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Patent number: 10597401
    Abstract: The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: March 24, 2020
    Assignee: Albany Molecular Research, Inc.
    Inventors: Robert Jason Herr, Brian Thomas Gregg, William Bert Geiss
  • Publication number: 20200055840
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Publication number: 20200048268
    Abstract: This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g., an ?5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an ?5-containing GABAA receptor agonist (e.g.
    Type: Application
    Filed: June 19, 2019
    Publication date: February 13, 2020
    Inventors: Belew Mekonnen, John A. Butera, Jianxing Huang, Hemantbhai Patel, Qin Jiang, Robert Jason Herr, Emily Elizabeth Freeman, Nicholas James Mayhew
  • Patent number: 10472346
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 12, 2019
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Publication number: 20190202803
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: February 27, 2019
    Publication date: July 4, 2019
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Patent number: 10246436
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: April 2, 2019
    Assignee: TREVENA, INC.
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C. K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Publication number: 20180134724
    Abstract: The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 17, 2018
    Inventors: Robert Jason HERR, Brian Thomas GREGG, William Bert GEISS
  • Publication number: 20180093967
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
    Type: Application
    Filed: October 30, 2015
    Publication date: April 5, 2018
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Patent number: 9896452
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: February 20, 2018
    Assignee: EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Yuanjun He, William Nguyen, Rong Jiang, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Publication number: 20170210725
    Abstract: The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
    Type: Application
    Filed: August 30, 2016
    Publication date: July 27, 2017
    Inventors: Aimee Crombie Speerschneider, Dennis Shinji Yamashita, Philip Michael Pitis, Michael John Hawkins, Guodong Liu, Tamara Ann Miskowski Daubert, Catherine C.K. Yuan, Robert Borbo Kargbo, Robert Jason Herr, Donna Romero, Gregory J. Pacofsky
  • Publication number: 20170101410
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Application
    Filed: October 20, 2016
    Publication date: April 13, 2017
    Inventors: Theodore M. Kamenecka, Yuanjun He, William Nguyen, Rong Jiang, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Patent number: 9499517
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 22, 2016
    Assignee: Eolas Therapeutics, Inc.
    Inventors: Theodore M. Kamenecka, Yuanjun He, William Nguyen, Rong Jiang, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Patent number: 9440982
    Abstract: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: September 13, 2016
    Assignee: Eolas Therapeutics, Inc.
    Inventors: Theodore M. Kamenecka, Yuanjun He, Rong Jiang, William Nguyen, Xinyi Song, Robert Jason Herr, Qin Jiang
  • Publication number: 20160229887
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: August 22, 2014
    Publication date: August 11, 2016
    Applicant: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco Gerald Salituro, Robert Jason Herr, Robert Borbo Kargbo
  • Publication number: 20140031287
    Abstract: The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.
    Type: Application
    Filed: August 20, 2013
    Publication date: January 30, 2014
    Applicant: Emisphere Technologies, Inc.
    Inventors: Robert Jason Herr, Louis Nickolaus Jungheim, John McNeill McGill, Kenneth Jeff Thrasher, Muralikrishna Valluri